Mirae Asset Global Investments’s Nektar Therapeutics NKTR Stock Holding History

Mirae Asset Global Investments’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,314	Closed	-$255K	–	2569
2022 Q3	$255K	Buy	5,314 +1,537	+41%	+$91.4K	﹤0.01%	2234
2022 Q2	$215K	Buy	+3,777	New	+$238K	﹤0.01%	2127
2019 Q3	–	Sell	-451	Closed	-$240K	–	1452
2019 Q2	$240K	Sell	451 -69	-13%	-$34.6K	﹤0.01%	1331
2019 Q1	$262K	Buy	+520	New	+$308K	﹤0.01%	1220
2018 Q4	–	Sell	-514	Closed	-$470K	–	1326
2018 Q3	$470K	Sell	514 -743	-59%	-$634K	﹤0.01%	1046
2018 Q2	$921K	Sell	1,257 -206	-14%	-$238K	0.01%	525
2018 Q1	$2.33M	Buy	+1,463	New	+$1.88M	0.03%	339
2016 Q4	–	Sell	-1,506	Closed	-$388K	–	545
2016 Q3	$388K	Buy	+1,506	New	+$388K	0.01%	472

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Mirae Asset Global Investments's NKTR Position: Q4 2022 in Review

Mirae Asset Global Investments sold out of Nektar Therapeutics (NKTR) in Q4 2022, closing a stake of 5,314 shares — an estimated $255K sold.

Mirae Asset Global Investments first reported a position in NKTR in Q3 2016 and held it in 8 quarters. The position peaked at $2.33M in Q1 2018. 214 funds tracked by Wall St. Rank hold NKTR as of Q4 2022.

Mirae Asset Global Investments reported no remaining Nektar Therapeutics position as of Q4 2022 after selling out during the quarter.
Mirae Asset Global Investments sold 5,314 Nektar Therapeutics shares in Q4 2022, an estimated $255K.
Mirae Asset Global Investments first reported a position in Nektar Therapeutics in Q3 2016 and held it in 8 quarters.
Mirae Asset Global Investments's Nektar Therapeutics position peaked at $2.33M in Q1 2018.
214 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2022.

Based on Mirae Asset Global Investments's 13F filing for Q4 2022, filed 9 Feb 2023.